Moderna, Inc. (MRNA)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$1,909.0M
Cash & Equivalents
$630.0M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$18,891M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05668741 A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF) PHASE2 Active Not Recruiting 26

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for MRNA.

SEC EDGAR Filings

All SEC filings for Moderna, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.